Paroxetine: current status in psychiatry (Q36730643)

15 August 2017

1 reference

title

Paroxetine: current status in psychiatry (English)

1 reference

15 August 2017

1 reference

ChEBI release 2020-05-28

Chi-Un Pae

1

1 reference

15 August 2017

Ashwin A Patkar

series ordinal

2

1 reference

15 August 2017

publication date

1 February 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

107-120

1 reference

Paroxetine controlled release

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Systematic review and guide to selection of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Paroxetine: an update of its use in psychiatric disorders in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Treating Chronic Tension‐type Headache Not Responding to Amitriptyline Hydrochloride With Paroxetine Hydrochloride: A Pilot Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Effects of SSRIs on sexual function: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Antidepressant drugs during pregnancy and infant congenital heart defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Delivery outcome after the use of antidepressants in early pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Pharmacotherapy of depression in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Clinical problem-solving. A bitter tale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Did regulators fail over selective serotonin reuptake inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Manufacturer admits increase in suicidal behaviour in patients taking paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

The impact of psychotherapists and primary physicians on suicide and other violent deaths in a rural area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

The relationship between antidepressant medication use and rate of suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Suicide risk during antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Antidepressants and the risk of suicidal behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Discontinuing or switching selective serotonin-reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Advances in drug delivery: improved bioavailability and drug effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Psychopharmacological treatment of major depressive disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.107

21 January 2018

Identifiers

DOI

10.1586/14737175.7.2.107

1 reference

15 August 2017

1 reference